• Impala Healthtech Research develops digital solutions to support clinical decisions and healthcare innovation.
• The company offers R&D, impact evaluation, and market strategy services for health technologies.
• Its flagship platform DIGAMS uses AI to guide antimicrobial treatment decisions in real time.

Chraish Miiro operates as a Ugandan pharmacist and healthtech innovator, and he co-founded and leads Impala Healthtech Research, a company focused on developing digital solutions for the healthcare sector.

The company launched in 2024 and positions itself as a strategic partner that supports decision-making in the design and commercialization of health solutions. It delivers services across three core areas: research and development, impact evaluation, and commercial strategy support.

The company conducts exploratory studies to identify urgent healthcare challenges, and it designs technology solutions tailored to those needs. It also carries out both ongoing and ad hoc research covering health system performance, access to care, service delivery, sector economics, and pharmaceutical issues.

Impala Healthtech Research also performs independent evaluations to measure the real-world effectiveness of health technologies developed internally or by partners. The company applies rigorous methodologies to ensure solutions meet performance standards and scale effectively under real conditions.

In addition, the company supports project developers in building market strategies. It conducts in-depth studies and analyses, and it uses collected data to design and test business models suited to high-potential innovations. It also identifies key levers required to maximize market adoption.

Its flagship solution, DIGAMS (Digital Antimicrobial Stewardship Platform), operates as a digital platform for antimicrobial management. It combines a marketplace for microbiology laboratories with a real-time, AI-powered decision-support tool that assists clinicians in prescribing antimicrobial treatments.

Chraish Miiro earned a bachelor’s degree in pharmacy from Makerere University in 2020. He began his professional career in 2016 as a public services payment evaluation officer at dfcu Bank. After completing pharmacy internships between 2019 and 2020, he joined Uganda’s National Drug Authority as an associate researcher. He later served as head of research at Mobiklinic from 2022 to 2025, where he supported technology solutions that improve healthcare access and delivery.

This article was initially published in French by Melchior Koba

Adapted in English by Ange J.A de Berry Quenum